ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.488,02
-0,60%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,00%
Euro vs US Dollar
1,08995
0,00%
Bitcoin
63.807,53
-1,61%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
05/06/202313h00Business WireANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual CareNASDAQ:AZNAstraZeneca PLC
05/06/202308h56Dow Jones NewsAstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria MetNASDAQ:AZNAstraZeneca PLC
04/06/202314h00Business WireTAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
03/06/202314h00Business WireLYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trialNASDAQ:AZNAstraZeneca PLC
02/06/202321h56Business WireIMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trialNASDAQ:AZNAstraZeneca PLC
02/06/202318h43Dow Jones NewsAstraZeneca Says Imfinzi Data Shows Improved Response in Gastric CancersNASDAQ:AZNAstraZeneca PLC
02/06/202318h13Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/06/202318h08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/06/202313h00Business WireLYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancerNASDAQ:AZNAstraZeneca PLC
01/06/202312h37Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/06/202312h17Dow Jones NewsTrending: AstraZeneca Gets Green Light for Cancer Treatment in USNASDAQ:AZNAstraZeneca PLC
01/06/202308h59Dow Jones NewsAstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development ProgramNASDAQ:AZNAstraZeneca PLC
01/06/202308h49Dow Jones NewsAstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentNASDAQ:AZNAstraZeneca PLC
26/05/202313h00Business WireIMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapyNASDAQ:AZNAstraZeneca PLC
26/05/202312h19Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
25/05/202313h00Business WireAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023NASDAQ:AZNAstraZeneca PLC
23/05/202320h15Business WireNew AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPDNASDAQ:AZNAstraZeneca PLC
22/05/202312h54Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
17/05/202313h00Business WireTAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trialNASDAQ:AZNAstraZeneca PLC
17/05/202312h44Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
17/05/202309h21Dow Jones NewsAstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In TrialNASDAQ:AZNAstraZeneca PLC
09/05/202317h37Business WireFARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patientsNASDAQ:AZNAstraZeneca PLC
09/05/202312h57Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
09/05/202312h47Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
09/05/202308h46Dow Jones NewsAstraZeneca Gets Broader Approval for Heart Failure Treatment in USNASDAQ:AZNAstraZeneca PLC
03/05/202317h31Dow Jones NewsSernova Shares Jump With AstraZeneca CollaborationNASDAQ:AZNAstraZeneca PLC
03/05/202313h53Dow Jones NewsSernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell ApplicationsNASDAQ:AZNAstraZeneca PLC
02/05/202315h12Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
02/05/202308h58Dow Jones NewsAstraZeneca Disappointed With US FDA Committee's Lynparza Vote OutcomeNASDAQ:AZNAstraZeneca PLC
27/04/202320h19Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

LSE
CBUG
Ish Ust 3-7yr ?
NASDAQ
CSCD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten